Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.99 USD | +2.05% | +13.68% | -36.36% |
May. 14 | Transcript : ScPharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | ScPharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 39.34M | Sales 2025 * | 95.73M | Capitalization | 144M |
---|---|---|---|---|---|
Net income 2024 * | -58M | Net income 2025 * | -30M | EV / Sales 2024 * | 3.66 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.5 x |
P/E ratio 2024 * |
-2.72
x | P/E ratio 2025 * |
-5.44
x | Employees | 136 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.28% |
Latest transcript on scPharmaceuticals Inc.
1 day | +2.05% | ||
1 week | +13.68% | ||
Current month | +2.05% | ||
1 month | -14.38% | ||
3 months | -34.80% | ||
6 months | -27.32% | ||
Current year | -36.36% |
Managers | Title | Age | Since |
---|---|---|---|
John Tucker
CEO | Chief Executive Officer | 61 | 16-12-31 |
Rachael Nokes
DFI | Director of Finance/CFO | 49 | 14-08-31 |
John Mohr
CTO | Chief Tech/Sci/R&D Officer | - | 17-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 13-12-31 | |
Klaus Veitinger
BRD | Director/Board Member | 62 | 17-11-20 |
John Tucker
CEO | Chief Executive Officer | 61 | 16-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +4.20% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 3.99 | +2.05% | 109,609 |
24-05-31 | 3.91 | -2.49% | 119,521 |
24-05-30 | 4.01 | +2.30% | 147,255 |
24-05-29 | 3.92 | +3.02% | 164,598 |
Delayed Quote Nasdaq, June 03, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.36% | 141M | |
+42.60% | 739B | |
+32.34% | 598B | |
-5.74% | 353B | |
+17.79% | 318B | |
+3.37% | 285B | |
+16.47% | 240B | |
+9.26% | 210B | |
-5.07% | 206B | |
+6.74% | 164B |
- Stock Market
- Equities
- SCPH Stock